Rana R. McKay, MD, expects the upcoming ESMO conference in October to deliver a wealth of research, notably the RADICALS-RT trial on post-prostatectomy radiotherapy timing and the AMG 509 phase 1 study in patients with metastatic castration-resistant prostate cancer.
Additionally, attendees can anticipate findings from studies like EMBARK, STAMPEDE subset analyses, and the ARTO trial, along with other new data that will be presented in the abstract sessions.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ESMO 2023: Anticipating Advances in Prostate Cancer Research - Medscape - Oct 12, 2023.
Comments